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Mouse IgG3 is highly protective against several life-threatening bacteria. This isotype 
is the only one among mouse IgGs that forms non-covalent oligomers, has increased 
functional affinity to polyvalent antigens, and efficiently agglutinates erythrocytes. IgG3 
also triggers the complement cascade. The high efficacy of protection after passive 
immunization with IgG3 is correlated with the unique properties of this isotype. Although 
the features of IgG3 are well documented, their molecular basis remains elusive. Based 
on functional analyses of IgG1/IgG3 hybrid molecules with swapped constant domains, 
we identified IgG3-derived CH2 domain as a major determinant of antibody oligomer-
ization and increased functional affinity to a multivalent antigen. The CH2 domain was 
also crucial for efficient hemagglutination triggered by IgG3 and was indispensable for 
complement cascade activation. This domain is glycosylated and atypically charged. 
A mutational analysis based on molecular models of CH2 domain charge distribution 
indicated that the functional affinity was influenced by the specific charge location. 
N-glycans were essential for CH2-dependent enhancement of hemagglutination and 
complement activation. Oligomerization was independent of CH2 charge and glycosyla-
tion. We also verified that known C1q-binding motifs are functional in mouse IgG3 but 
not in IgG1 framework. We generated for the first time a gain-of-function antibody with 
properties transferred from IgG3 into IgG1 by replacing the CH2 domain. Finding that the 
CH2 domain of IgG3 governs unique properties of this isotype is likely to open an avenue 
toward the generation of IgG3-inspired antibodies that will be protective against existing 
or emerging lethal pathogens.
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inTrODUcTiOn
There are four subclasses of mouse IgGs: IgG1, IgG2a, IgG2b, and IgG3. Although structurally very 
similar, they significantly differ in their functions (1). Mouse IgG3s are particularly interesting, 
because they are able to form oligomers, which strongly influences their biological activities (2).
Mouse IgG3 was described for the first time almost 50  years ago (3) and different aspects of 
its biology have been investigated by several groups. The propensity of IgG3 oligomerization was 
noticed already by its discoverers (3). Then, other researchers reported cooperative binding of IgG3 
to a multivalent antigen (4,  5). Although the initial report on IgG3 oligomerization concerned 
molecules in solution (3), later studies revealed that binding to multivalent antigens promoted IgG3 
2Klaus and Bereta CH2 Governs Mouse IgG3 Properties
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1096
intermolecular interactions, which in turn resulted in its increased 
functional affinity to the antigen (4). This phenomenon depended 
on Fc, because IgG3 F(ab’)2 fragments did not bind to the antigen 
cooperatively (4). However, the exact molecular mechanism of 
IgG3 oligomerization remains unknown.
IgG3 is a major component of cryoglobulins in mice (2). Cryo­
globulins are plasma proteins that reversibly precipitate at low 
temperatures or at high concentrations (6). Cryogenic activity of 
IgG3 was shown to correlate with its ability to oligomerize, with 
the presence of charged residues in the variable region and the 
level of sialylation (7).
Also, IgG3 was reported as exceptionally effective in preventing 
or fighting several life­threatening microbial infections, e.g., with 
Neisseria meningitidis (8) or Bacillus anthracis (9). A comp arison 
between the four mouse IgG subclasses with the same variable 
region specific to B. anthracis capsule proved that only IgG3 is 
protective against pulmonary anthrax in a mouse model (9). 
Importantly, mouse–human chimeric antibodies containing a con­
stant region of any human IgG subclass were not effective, although 
they had the same variable region as the protective mouse IgG3 
(10). These reports indicated that mouse IgG3 constant region has 
unique properties, but the authors only speculated about possible 
molecular mechanisms behind the observed phenomenon.
The exceptional characteristic of IgG3 was also confirmed 
by our previous report that among mouse IgGs recognizing a 
surface antigen of erythrocytes only IgG3s are able to agglutinate 
the cells (11). We rejected the hypothesis that IgG3­mediated 
hemagglutination results from oligomerization of the antibodies, 
because IgG3 F(ab’)2 was sufficient to trigger hemagglutination. 
Molecular modeling indicated that IgG3 has a larger span of Fab 
arms than other IgG subclasses. IgG3 has a long­upper hinge that 
may extend the Fab range, but whether this may account for the 
ability to hemagglutinate was not verified experimentally.
Here, we present the results of our attempts to find molecular 
determinants of the properties of mouse IgG3. Our experimental 
model comprised two antibodies (M18 and O10) specific to 
antigen B of the ABO blood group system (11). Antigen B is a pen­
tasaccharide O­glycan attached to numerous proteins and lipids 
on the erythrocyte surface. The large quantity and high density of 
the antigen, as well as a strong negative charge of the erythrocyte 
surface, could be considered as a safe and easy­to­handle model of 
a pathogen surface. We generated many muteins of IgG3 molecules 
and analyzed their functional affinity to the antigen as well as their 
ability to hemagglutinate and oligomerize. The results showed 
that IgG3­derived CH2 domain determines antibody oligomeri­
zation and increases its affinity to the antigen. This domain also 
strongly enhances agglutination of erythrocytes bearing B antigen. 
Moreover, we investigated complement activation by the muteins, 
and we confirmed that known C1q­binding motifs are functional 
in mouse IgG3 but not in the mouse IgG1 framework.
MaTerials anD MeThODs
generation of Vectors coding for  
antibody Muteins
Expression vectors coding for heavy chain muteins with swapped 
domains or mutated CH2 were generated using synthetic nucleic 
acids (Gene Art, Germany) cloned into pFUSEss­CHIg­mG1_
M18 (Addgene #82357) or pFUSEss­CHIg­mG3_M18 (Addgene 
#82356) plasmids (11). Only endogenous restriction sites present 
in the ORFs were used for cloning. Vectors coding for other 
muteins were prepared with Q5­based site directed mutagenesis 
kit (NEB). All plasmids coding for heavy chain variants of M18 
antibody are available via Addgene repository along with their 
full sequences and maps, accession numbers: 105849–105863. 
Plasmids encoding O10 antibody variants were obtained by 
replacing the sequence coding for M18 variable fragment with a 
corresponding O10­derived cDNA using EcoRI and AfeI restric­
tion sites in the vectors coding for M18 heavy chain variants. The 
sequence of O10 antibody is proprietary and cannot be disclosed. 
All plasmids were verified using Sanger sequencing (Genomed, 
Poland) or NGS (Addgene).
Production of antibodies
The recombinant antibodies were transiently expressed 
in HEK293T  cells cultured in DMEM with 4.5  g/l glucose 
(Lonza) supplemented with 10% FBS (Biowest). The cells were 
co­transfected with plasmids coding for a heavy chain and a 
cognate light chain using Lipofectamine2000 (Thermo) or PEI 
MAX (Polysciences, MW 40,000). In the case of M18 variants, 
the plasmid pFUSE2ss­CLIg­mK_M18 (Addgene, #82358) (11) 
coding for M18 light chain was used. A similar plasmid coding 
for O10 light chain was used for expression of O10 variants. 
Hybridoma­derived M18 IgG3 was produced as described pre­
viously (11). The antibodies were purified using CaptureSelect 
LC­kappa (mur) affinity matrix (Thermo) according to instruc­
tions of the supplier. Glycine–HCl (100 mM, pH 2.0) was used 
for elution.
Production of igg3 F(ab’)2
A sequence encoding IgG2b core hinge, HA tag and a stop 
codon was cloned into pFUSEss­CHIg­mG3_M18 downstream 
of the sequence coding for the upper hinge of M18. Sequences 
of the upper and core hinges of the antibodies are described by 
Dangl et al (12). Mouse IgG2b core hinge contains four cysteine 
residues that allow an efficient association of Fab’ fragments into 
F(ab’)2 (13). Recombinant F(ab’)2 was expressed as described for 
other antibodies. Alternatively, F(ab’)2 was produced by enzy­
matic digestion with IdeZ (NEB) according to the manufacturer’s 
protocol.
Measurements of antibody concentration
Antibody concentrations in cell culture media were measured 
using a standard sandwich ELISA on plates coated with sheep 
anti­mouse Fab polyclonal antibody (Jackson Laboratory, cat. 
#515­005­072, lot #105461). Goat anti­mouse kappa polyclonal 
antibody (1:3,000, BioRad, cat. #105008, batch #160617), HRP­
labeled streptavidin (1:40,000, Sigma), and the TMB substrate 
for HRP (BD Bioscience) were used for detection. The HRP­
dependent colorogenic reaction was stopped with 1  M HCl, 
and the absorbance at 450  nm was read using the microplate 
spectrophotometer Synergy H1 operated by Gen5 2.00 Software 
(BioTek). Purified M18 (IgG3) and MCP21 (IgG1, Sigma) were 
used as standards. Concentrations of muteins were calculated 
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based on their Fab type (IgG1­ or IgG3­type Fab). BCA assay 
(Sigma) was used for measurements of purified antibody concen­
trations with bovine γ­globulin (Thermo) as a reference.
antibody Binding to immobilized 
erythrocytes
Polystyrene plates were coated with 50 µg/ml poly­l­Lys (Sigma) 
for 1 h at room temperature (RT). Then, 100 µl of 0.1% (hematocrit) 
suspension of red blood cells in PBS were added to the wells and 
the cells were allowed to settle for 1 h at RT. After gentle aspiration 
of the solution, the cells were fixed using 0.025% glutaraldehyde 
for 40 min. Endogenous peroxidase activity was blocked with 3% 
H2O2 for 1 h. The plates were blocked overnight with 0.2% gelatin 
in PBS containing 0.05% Tween­20 at 4°C. Then, the cells were 
incubated with serial dilutions of cell culture media containing 
analyzed antibodies followed by detection with anti­mouse kappa 
polyclonal antibody conjugated with biotin (1:3,000, BioRad) 
and HRP­labeled streptavidin (1:40,000, Sigma). All reagents 
were diluted in the blocking buffer. The colorogenic reaction 
was performed, and the absorbance at 450 nm was measured as 
described above.
c1q Binding
Duplicates of polystyrene plates were coated with 6  µg/ml 
of BSA conjugated with the discriminating trisaccharide of 
the B antigen (Dextra Laboratories, cat #NGP6323, batch 
#ATDX232­039) overnight at 4°C, blocked with 1% BSA in PBS 
(1 h) and incubated with serial dilutions of cell culture media 
containing O10 muteins (2 h). Then, one set of plates was used 
for evaluation of C1q binding by analyzed antibodies; and the 
plates were incubated with 2 µg/ml of C1q purified from human 
serum (Biorad, cat. #22215504, batch #130815; 2  h) and next 
with HRP­labeled anti­human C1q polyclonal antibody (1:400, 
Abcam, cat. #ab46191, lot #GR205436­5; 1  h). The second set 
of plates was used to analyze quantities of the muteins bound 
to the immobilized antigen; and the plates were incubated with 
anti­mouse kappa polyclonal antibody conjugated with biotin 
(1:3,000, BioRad, 2 h) and HRP­labeled streptavidin (1:40,000, 
Sigma; 1 h).
Absorbance of HRP product was measured as described 
above. Each incubation step was preceded by extensive washing 
with 0.05% Tween­20 in PBS. The antibodies, streptavidin, and 
C1q were diluted in 0.1% BSA in PBS. All incubations, except 
plate coating, were at RT.
The normalized C1q binding (a) was calculated by dividing 
the signal corresponding to C1q binding (b) by the signal cor­
responding to bound antibody (c).
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complement cascade activation
Washed human red blood cells suspended to a hematocrit of 2% 
were coated with 3 µg/ml or 1.5 µg/ml of the analyzed antibodies 
for 1.5 h at RT, washed twice with PBS and resuspended in PBS 
with Ca2+ and Mg2+. Then, the same volume of human comple­
ment serum (Sigma, cat. #S1764, lot #SLBS5471V, #SLBQ0752V 
or #SLBP0461V) diluted to 7 CH50 U/ml in PBS with Ca2+ and 
Mg2+ was added to the coated red blood cells. The samples were 
centrifuged after 2 h of incubation at 37°C, and the absorbance of 
released hemoglobin was measured in the supernatants at 540 nm.
red Blood cells and agglutination
Standard human red blood cells were purchased from Regional 
Centre of Blood Donation and Blood Treatment in Katowice, 
Poland. Agglutination tests were performed in 96­flat bottom 
plates. Serially diluted solutions of analyzed antibodies (100 µl) 
were gently mixed with 0.45% (hematocrit) suspension of red 
blood cells. The level of agglutination was analyzed using a phase­
contrast microscope after 20 min of moderate shaking. A six­point 
scale was used for evaluation of agglutination intensity: from 4+ 
(complete cell aggregation), to 3+, 2+, 1+, ± to a negative score. 
The agglutination score reflects both the size of aggregates and 
quantity of non­agglutinated cells.
igg3 self-association assay
Oligomerization of IgG3 was analyzed similarly to the method 
described by Abdelmoula et al (2). Three different concentrations 
of the purified domain muteins with M18 variable region (150, 
100, and 20  µg/ml) were incubated with non­mutated, bioti­
nylated IgG3 M18 (100 ng/ml) for 72–96 h at 4°C in the presence 
of 4% BSA (Sigma, cat. #A9576). Then, the antibody complexes 
were precipitated by adding 50% PEG­6000 (Sigma) to the final 
concentration of 7.5%. After 1 h of incubation on ice, the samples 
were centrifuged (30 min, 3,000 × g, 4°C). The supernatants were 
preserved for further analysis, and the precipitates were washed 
with ice­cold 7.5% PEG­6000 in PBS and centrifuged again 
(30 min, 3,000 × g, 4°C). Then, the precipitates were dissolved 
in PBS with 0.1% BSA by pipetting at 37°C. Biotinylated IgG3 in 
the precipitates and supernatants was quantified using ELISA on 
polystyrene plates coated with streptavidin (8 µg/ml, Thermo, cat. 
#434301, lot #RB233354). Bound biotinylated IgG3 was detected 
using rabbit monoclonal antibody M111­2 (1:1,000, Abcam, cat. 
#ab125904, lot #C050311, #GR157092­1) and HRP­labeled goat 
anti­rabbit polyclonal antibody (1:3,000, Sigma, cat #A6667). The 
absorbance of HRP product was measured as described above.
sDs-Page and Western Blotting
Samples were resolved in 8 or 12% polyacrylamide gels under 
non­reducing or reducing conditions according to the protocol 
of Laemmli (14). After wet electrotransfer onto PVDF mem­
brane and blocking with 4% skim milk in PBS, the samples were 
probed with anti­mouse kappa polyclonal antibody conjugated 
with biotin (1:3,000, BioRad) and HRP­labeled streptavidin 
(1:40,000, Sigma). Alternatively, rabbit anti­HA tag polyclonal 
antibody (1:10,000, Abcam, cat. #ab9110) and HRP­labeled goat 
anti­rabbit F(ab’)2 polyclonal antibody (1:10,000, Sigma, cat. 
FigUre 1 | Hemagglutination induced by M18 IgG3 and its F(ab’)2. (a) Integrity of generated F(ab’)2 was verified using SDS-PAGE. In the case of the purified 
antibody digested with IdeZ, the gels were stained with Coomassie Brilliant Blue (CBB). Recombinant F(ab’)2 was equipped with HA tag and its integrity was 
confirmed using Western blotting with anti-HA tag antibody. The molecular mass of non-reduced F(ab’)2 is about 120 kDa. HC, heavy chain; HC’, heavy chain 
fragments generated after IdeZ cleavage; LC, light chain; (B) Microscopic images of erythrocytes agglutinated by equal molar concentrations of IgG3 antibody  
and its F(ab’)2. The antibody fragment was obtained from native IgG3 using IdeZ digestion.
TaBle 1 | M18 full-length IgG3 and M18 IgG3 F(ab’)2 induced hemagglutination with different efficacy.
concentration (nM) score of hemagglutinationa concentration (nM) score of hemagglutination
native igg3 F(ab’)2 obtained using ideZ recombinant igg3 recombinant F(ab’)2
82.5 ++++ + 93 ++++ ±
41.3 ++++ ± 46.5 ++++ –
20.6 ++++ – 23.3 ++++ –
10.3 ++++ – 11.6 +++ –
5.2 +++ – 5.8 +++ –
2.6 +++ – 2.9 + –
1.3 ++ – 1.5 ± –
0.6 ± – 0.7 – –
0.3 – – 0.4 – –
aRepresentative results of three independent experiments.
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#A6667, lot #SLBG3029) were used. Mouse IgG3 heavy chain was 
detected using goat antiserum to mouse IgG3 (1:500, Sigma, cat. 
#ISO2) and rabbit anti­goat polyclonal antibody (1:5,000, Sigma, 
cat. #A4174). Bands were visualized using Immobilon Western 
Chemiluminescent Substrate for HRP (Millipore). The images 
were captured and analyzed using Fusion Fx apparatus with the 
Fusion Capt Advance Fx5 program (Vilbert Lourmat, France).
resUlTs
comparison of hemagglutination induced 
by igg3 and igg3 F(ab’)2
In our previous work, we reported that F(ab’)2 obtained from 
IgG3 induces agglutination of erythrocytes bearing a cognate 
antigen (11). However, as shown below, complete IgG3 aggluti­
nates erythrocytes more efficiently than its F(ab’)2, i.e., a much 
higher concentration of F(ab’)2 than that of the intact molecule 
is required for agglutination. We compared hemagglutination 
triggered by: (i) native, purified, full­length IgG3, and its F(ab’)2 
obtained by IdeZ protease digestion and (ii) culture media of cells 
producing recombinant IgG3 or recombinant F(ab’)2 (Table 1). 
Concentrations of IgG3 and F(ab’)2 in the media were measured 
using ELISA and equalized for the comparative tests. We verified 
the quality of analyzed proteins and confirmed that recombinant 
IdeZ protease, which cleaves IgG3 at a single site in its hinge 
region, generates homogeneous F(ab’)2 (Figures 1A,B). Based on 
this analysis, we estimated that IgG3 was about 32 to 64­times 
more potent than its F(ab’)2 in hemagglutination (Table  1; 
Figure  1B). The results indicate that the Fc of IgG3 strongly 
enhances hemagglutination induced by this isotype.
The ch2 Domain Derived From igg3 
enhanced hemagglutination efficacy  
of an antibody
Our previous attempts to explain the mechanism of IgG3­dependent 
hemagglutination brought us to the hypothesis that the elongated 
hinge of IgG3 determines its hemagglutination ability (11). In light 
of the new results, the hypothesis required revision. To elucidate 
FigUre 2 | Hemagglutination induced by IgG1 and IgG3 muteins. (a) Generated domain muteins and their nomenclature. (B) Microscopic images of 
hemagglutination induced by the domain muteins. All antibodies were used at a concentration of 1.5 µg/ml, except of O10 IgG1_CH2-3 that was used  
at 3 µg/ml. Scale bar—100 µm; (c) Hemagglutination induced by selected O10 muteins used at 10 µg/ml.
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which domains of IgG3 are crucial for its hemagglutination abil­
ity, we generated a panel of domain muteins of agglutinating IgG3 
and non­agglutinating IgG1 isotypes (Figure 2A). We generated 
pairs of IgG1 and IgG3 molecules with the same variable regions 
and with swapped: (i) hinge regions; (ii) hinge regions +  CH1 
domains; (iii) CH2 domains, and (iv) CH3 domains and searched 
for muteins of two types: loss­of­function in the case of IgG3 and 
gain­of­function in the case of IgG1.
Preliminary experiments showed that hinge swapping between 
IgG1 and IgG3 hinders disulfide bonds formation between 
chains of the muteins (Figure S1 in Supplementary Material). 
However, the IgG1_h­3 and IgG3_h­1 variants were functional 
and their affinity to the antigen was similar to that of the parental 
molecules (shown in Figure 3). As demonstrated by Dall’Acqua 
et  al., immunoglobulins with modified hinges frequently form 
functional heterotetramers (HC)2(LC)2 despite the lack of 
disulfide bonds between the chains (15). Gel filtration confirmed 
that IgG1_h­3 and IgG3_h­1 have molecular mass greater than 
150 kDa and form stable (HC)2(LC)2 heterotetramers (data not 
shown). To make sure that the results of the following experiments 
are not the consequence of incorrect assemblies of the hinge­
swapped muteins, we also generated muteins with swapped frag­
ments comprising hinge regions and CH1 domains. All muteins 
were successfully expressed and their integrity was verified using 
SDS­PAGE and Western blotting (Figure S1 in Supplementary 
Material).
Then, we compared hemagglutination induced by the muteins 
(Tables 2 and 3; Figures 2B,C). The results showed that neither 
TaBle 2 | Scores of hemagglutination induced by M18 variants.
conc. (μg/ml) Parental iggs swap of hinge regions swap of ch1 + hinge 
domains
swap of ch2 
domains
swap of ch3 
domains
igg1 igg3 igg1_ 
h-3
igg3_ 
h-1
igg1_ 
ch1h-3
igg3_ 
ch1h-1
igg1_ 
ch2-3
igg3_ 
ch2-1
igg1_ 
ch3-3
igg3_ 
ch3-1
ia ii i ii i ii i ii i ii i ii i ii i ii i ii i ii
1.500 – – +++ ++ – – +++ +++ – – +++ +++ + + – + – ± ++ +++
0.750 – – +++ +++ – – + +++ – – ++ +++ – ± – – – – + ++
0.375 – – ++ +++ – – ± + – – + ++ – – – – – – ± ++
0.188 – – + ++ – – – – – – ± + – – – – – – – –
0.094 – – ± ± – – – – – – – – – – – – – – – –
0.047 – – – – – – – – – – – – – – – – – – – –
aResults of two independent experiments designated as I and II.
FigUre 3 | Antigen binding by the domain muteins. M18 and O10 antibodies are specific to B-antigen present on human erythrocytes. B-antigen is a 
pentasaccharide O-glycan. O10 antibody, but not M18, binds terminal fragment of the antigen, called B-trisaccharide. Antigen–antibody interaction was analyzed 
using ELISA on immobilized erythrocytes. In the case of O10, plates coated with BSA conjugated with the synthetic B-trisaccharide were also used. The plots 
present mean values from two independent experiments performed in duplicates. Results obtained for IgG1 and IgG3, the parental molecules, are presented on 
each plot to allow convenient comparisons.
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TaBle 3 | Scores of hemagglutination induced by O10 variants.
conc. (μg/ml) Parental iggs swap of hinge regions swap of hinge + ch1 
domains
swap of ch2 
domains
swap of ch3 
domains
igg1 igg3 igg1_h-3 igg3_h-1 igg1_
ch1h-3
igg3_
ch1h-1
igg1_
ch2-3
igg3_
ch2-1
igg1_
ch3-3
igg3_
ch3-1
ia ii i ii i ii i ii i ii i ii i ii i ii i ii i ii
3.000 – – ++ ++ – – +++ ++ – – +++ ++ + + – ± – + +++ +++
1.500 – – +++ +++ – – +++ ++ – – +++ ++ ± – – – – – + ++
0.750 – – ++ ++ – – ++ ++ – – + ++ – – – – – – ± ±
0.375 – – + + – – + + – – ± ± – – – – – – – –
0.188 – – ± ± – – ± ± – – – + – – – – – – – –
0.094 – – – – – – – – – – – – – – – – – – – –
aResults of two independent experiments designated as I and II.
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the CH1 domain nor the hinge determined the agglutination 
ability of IgG3. The introduction of the CH3 domain from IgG1 
into IgG3 resulted in a molecule with slightly reduced hemag­
glutination score but CH3 from IgG3 did not translate into IgG1 
ability of hemagglutination. In contrast, CH2 swapping led to the 
generation of IgG1 mutein (IgG1_CH2­3) that gained the ability 
of hemagglutination (Tables 2 and 3). Moreover, the paired IgG3 
mutein (IgG3_CH2­1) had about 16­times reduced hemaggluti­
nation score in comparison to the parental IgG3.
IgG1_CH2­3 as a gain­of­function mutein was particularly 
interesting, because it indicated that the CH2 domain of IgG3 is the 
one critical for hemagglutination. However, IgG1_CH2­3 aggluti­
nated erythrocytes with considerably lower score than native IgG3.
We also compared hemagglutination efficacy of native M18 
IgG3 and its deglycosylated form. Deglycosylated IgG3 agglu­
tinated erythrocytes about 16­times weaker than the native 
molecule (Table S1 in Supplementary Material).
To sum up, the ability of IgG3 to agglutinate erythrocytes results 
from its unique structure, in which the CH2 domain is especially 
important and strongly enhances the efficacy of the process. 
Although the IgG3 F(ab’)2 is sufficient to trigger hemagglutina­
tion, its efficacy is much lower in comparison to full­length IgG3, 
probably just due to the lack of the CH2 domain. The hinge region 
seems to have little influence on agglutination ability, because 
IgG3 with the IgG1­derived hinge agglutinated erythrocytes only 
slightly less effectively than the parental molecule.
igg3 constant Domains Modify Functional 
affinity to an antigen
There is a general agreement that the increased functional affinity 
of IgG3 results from an avidity effect caused by the interactions 
between the Fc fragments of the molecules (16). In line with that, 
we observed that IgG3 binds to erythrocytes much more effi­
ciently than IgG1 with the same variable region and much more 
efficiently than IgG3­derived F(ab’)2 (Figure S2 in Supplementary 
Material). Some authors discussed also the potential role of 
N­glycans in IgG3 unique properties (17, 18), but we did not 
observe any differences in antigen binding between control and 
deglycosylated antibody (Figure S2 in Supplementary Material).
Aiming to understand why IgG3 has increased functional 
affinity, we analyzed antigen binding by the domain muteins 
(Figure  3). The results showed that the hinge region of IgG3 
does not influence the functional affinity of the antibody, 
but muteins with the swapped CH1 +  hinge, CH2, or CH3 
domains had changed functional affinity. The introduction 
of IgG3­derived CH1 +  hinge or CH2 domain into the IgG1 
framework enhanced antigen binding in comparison to the 
parental IgG1. Conversely, the paired IgG3 muteins with IgG1­
derived CH1 + hinge or CH2 had reduced functional affinity. 
The swapping of the CH3 domains resulted in the IgG3 mutein 
with decreased affinity, but in the paired IgG1 mutein, the effect 
was not substantial. The calculated EC50 values of antigen bind­
ing for IgG3 muteins indicated that the CH2 domain had the 
strongest influence on IgG3­antigen interaction (Table 4). CH2 
swapping resulted in IgG3 muteins with 3–12 times decreased 
functional affinity.
Overall, the results indicate that the higher (in comparison to 
IgG1) functional affinity of IgG3 to its antigen does not depend 
on a separate constant domain of this isotype, but rather is an 
additive result of discrete properties of the all three constant 
domains CH1, CH2, and CH3, but not the hinge region. Of all 
the constant domains, CH2 contributes the most to the high 
functional affinity of IgG3.
Fc-Dependent Oligomerization of the 
Domain Muteins
The hallmark of mouse IgG3 is its ability to oligomerize. The 
process depends on Fc fragment, but its exact molecular mecha­
nism is unknown. We analyzed whether the domain muteins 
form non­covalent complexes using polyethylene glycol (PEG) 
precipitation with a labeled IgG3 probe (2). In comparison to the 
original method, we used biotinylated IgG3 instead of radiolabeled 
IgG3. The IgG3­biotin interacted with oligomerizing muteins and 
the complexes comprised the mutein and the probe. The com­
plexes were precipitated using PEG, and then, IgG3­biotin was 
quantified in precipitates and supernatants using ELISA. A high 
precipitate/supernatant ratio of IgG3­biotin quantities indicates 
that the mutein forms oligomers.
The experiment showed that 5 out of 10 analyzed molecules 
form PEG­precipitable oligomers—IgG3 (control) and all IgG3 
muteins but the one containing IgG1­derived CH2 domain and 
none of IgG1 muteins but the one with IgG3­derived CH2 domain 
FigUre 4 | Oligomerization of the domain muteins. The antibodies (M18 
variants, 150 µg/ml) were incubated at 4°C and oligomers were precipitated 
using PEG. Biotinylated IgG3 was used as a probe that oligomerized with the 
muteins and became a part of the complexes. The charts present results 
from two independent experiments. The results obtained for 100 and 20 µg/
ml of the muteins are shown in Figure S3 in Supplementary Material. A 
percentage of the total IgG3-biotin detected in the precipitates and the 
supernatants is presented in Figure S4 in Supplementary Material.
TaBle 4 | EC50 of mutein binding to the antigen calculated using data from Figure 3.
Variable region of the mutein and type of the antigen ec50 of mutein binding (nM)
igg3 igg3_h-1 igg3_ch1h-1 igg3_ch2-1 igg3_ch3-1
M18 (erythrocytes) 0.24 ± 0.02 0.38 ± 0.01 0.61 ± 0.03 0.86 ± 0.04 0.87 ± 0.07
O10 (erythrocytes) 0.81 ± 0.01 0.88 ± 0.02 2.05 ± 0.06 9.75 ± 2.04 3.60 ± 0.29
O10 (B-trisaccharide conjugated to BSA) 0.50 ± 0.04 0.38 ± 0.02 1.15 ± 0.06 1.40 ± 0.03 0.79 ± 0.06
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(Figure 4). Oligomerization did not depend on CH2 glycosyla­
tion (Figure S5 in Supplementary Material). The results indicate 
that the CH2 domain is crucial for oligomerization of IgG3.
complement activation by the  
igg1 and igg3 Muteins
Similar to human antibodies, there are pronounced differences 
between mouse IgG subclasses in their ability to trigger comple­
ment cascade. Mouse IgG3 activates complement efficiently, 
whereas mouse IgG1 does not. Although there are many excel­
lent reports concerning correlation between human antibody 
structure and its ability of complement activation, the structural 
determinants of mouse antibodies that allow to trigger the cas­
cade are not precisely known.
The best characterized Ig with respect to complement activa­
tion is human IgG1, in which several amino acid residues were 
identified as crucial for the initiation of the complement cascade 
(Figure S6 in Supplementary Material) (19–21). The sequence 
alignment of human IgG1, mouse IgG1, and mouse IgG3 indicated 
that the majority of human IgG1 amino acid residues involved 
in complement activation are conserved in both mouse isotypes 
(Figure S6 in Supplementary Material). However, it revealed two 
differences between mouse IgG1 and IgG3 within the regions cor­
responding to those involved in C1q binding by human IgG1—in 
the N­terminal fragment of the CH2 domain (Val231­Ser238 in 
IgG1 and Ile234­Pro238 in IgG3, EU numbering (22)) and in the 
residue 322 (Figure S6 in Supplementary Material).
To verify whether these motifs are involved in complement 
activation by mouse IgG3, we generated additional muteins in 
which we swapped them between IgG1 and IgG3—IgG1_ILGGP 
(Val231Ile Pro232Leu Glu236Gly Val237Gly Ser238Pro); IgG3_
VPEVS (Ile234Val Leu235Pro Gly236Glu Gly237Val Pro238Ser); 
IgG1_Arg322Lys; IgG3_Lys322Arg, and a double mutein IgG1_
ILGGP_Arg322Lys. The IgG3 heavy chain containing VPEVS did 
not associate with a light chain and was not secreted (Figure 5A). 
Lys322Arg replacement completely abolished complement acti­
vation by IgG3 indicating that Lys322 is crucial for this process 
(Figures 5B,C). The three muteins of IgG1 did not bind C1q nor 
activated complement cascade indicating that the IgG1 framework 
prevents activation of complement (Figures  5B,C). The results 
showed that the known C1q­binding motifs are functional in the 
mouse IgG3 but not in the mouse IgG1 framework.
Some authors observed a correlation between hinge­depend­
ent segmental flexibility of an antibody and its ability to activate 
complement (12). Thus, the differences between activity of mouse 
IgG1 and IgG3 are frequently explained on the basis of the length 
of their hinges. We decided to empirically verify this hypothesis 
using the domain muteins.
First, we analyzed the binding of the complement cascade ini­
tiator (C1q) to the muteins (Figure 6A). The results showed that 
the hinge modification does not affect C1q binding. The swapping 
of the CH2 domain from IgG1 into IgG3 abolished C1q binding 
by the latter. Interestingly, the paired mutein (IgG1_CH2­3) did 
not gain the ability to strongly interact with C1q; its binding of 
C1q reached ~12% of that characteristic for native IgG3. Swapping 
of the CH1 + hinge domains or the CH3 domains between IgG1 
and IgG3 moderately diminished C1q binding by IgG3 and did 
not increase its binding by IgG1.
We also analyzed complement activation in serum triggered 
by erythrocytes coated with the domain muteins (Figure  6B). 
FigUre 5 | Functionality of known C1q-bining motifs in mouse IgG1 and mouse IgG3 frameworks. (a) IgG3_VPEVS did not associate with a light chain and was 
not secreted by the producing cells. (B) C1q binding by the muteins. Plates coated with BSA conjugated with the antigen, B-trisaccharide, were incubated with the 
muteins at 3 µg/ml (O10 variants). Then purified C1q was added. The muteins bind the antigen with different functional affinity. Thus, the C1q signal was normalized 
to the quantity of the bound antibody. Data used for calculation of the normalized binding are shown in Figure S7 in Supplementary Material. Error bars correspond 
to uncertainty calculated as presented in Section “Materials and Methods.” (c) Complement cascade activation by the muteins (3 µg/ml). Erythrocytes coated with 
the antibodies were incubated with complement serum. Complete lysis (100%) corresponds to water-induced lysis. In (a–c) representative results of two 
independent experiments are shown.
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The levels of erythrocyte lysis indicated that all muteins contain­
ing the CH2 domain derived from IgG3 activate complement 
cascade. The observed differences in C1q binding were not 
reflected by the different efficacy of the cascade triggering. The 
muteins with low (IgG1_CH2­3) or moderate (IgG3_CH1h­1, 
IgG3_CH3­1) ability of C1q­binding activated complement 
cascade with efficacy similar to that of the parental IgG3. It 
seems that in the case of the antibodies comprising IgG3­derived 
CH2 domain, even weak interaction with C1q was sufficient to 
effectively activate the whole complement cascade.
The results showed that both IgG1­ and IgG3­derived CH1, 
hinge, and CH3 domains are permissive for C1q binding and 
complement activation. The CH2 domain of IgG1 is a non­
permissive framework for the known C1q­binding motifs.
Overall, the results pointed to the CH2 domain as the major 
determinant of mouse IgG3 functions and unique properties of 
this isotype. In the last part of our work, we sought for features 
of the IgG3­derived CH2 domain that may account for IgG3 
distinctive characteristic.
Properties of Muteins With reversed 
charge of the ch2 Domains
The most striking difference between mouse IgG3­derived CH2 
and CH2 domains of other IgG subclasses is their charges; only the 
former has a strong positive charge. For example, at pH 7.0, the net 
charge of the CH2 domain of IgG1 is −2.6 and of IgG3 is +2.6 (cal­
culated using http://protcalc.sourceforge.net/). Hovenden et al. (9) 
found a correlation between the charge of CH2 domains of mouse 
IgG subclasses and their affinity to a negatively charged polyvalent 
antigen (poly­glutamic acid, poly­GA); and the high affinity of 
IgG3 to poly­GA was attributed to the charge of its CH2 domain.
We analyzed spatial distribution of charged residues on the CH2 
surface of IgG1 and IgG3 using previously obtained molecular 
models (11) and data deposited in PDB record 1IGY (Figure 7A). 
We identified 29 residues that differ between CH2 domains of 
mouse IgG1 and IgG3, 9 of which have different charge (Figure 
S9 in Supplementary Material). Based on the models, we selected 
four basic residues (His274, Lys282, Arg315, and Lys326) that are 
regularly spaced on the outer surface of the CH2 domain of IgG3 
FigUre 6 | Complement activation induced by the domain muteins. (a) C1q binding to the domain muteins (O10 variants). The data used for calculations  
are presented in Figure S7 in Supplementary Material. Error bars correspond to uncertainty calculated as described in Section “Materials and Methods.”  
(B) Complement cascade activation by the domain muteins. Erythrocytes coated with 3 µg/ml of the muteins were incubated with complement serum.  
100% lysis corresponds to water-induced lysis. The bars present mean values and standard deviation of duplicates from one experiment. Results obtained  
with 1.5 µg/ml of the muteins are presented in Figure S8 in Supplementary Material. (a,B) Representative results of two independent experiments.
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(Figure 7A; Figure S9 in Supplementary Material). The same resi­
dues in IgG1 are not charged. To verify whether CH2 charge influ­
ences IgG3 properties, we generated two muteins in which the four 
residues were swapped—IgG3_CH2charge (His274Gln Lys282Val 
Arg315Asn Lys326Ala) and IgG1_CH2charge (Gln274His 
Val282Lys Asn315Arg Ala326Lys). These muteins were expressed, 
correctly assembled, and soluble (Figure S1 in Supplementary 
Material). The introduced mutations reversed the charge of the 
CH2 domains. It was 0.6 and −0.7 at pH 7.0 for the CH2 domain 
of IgG1_CH2charge and IgG3_CH3charge, respectively.
We compared properties of the parental molecules and the 
muteins with modified CH2 charge. We observed that the charge 
influenced binding to erythrocytes (Figure 7B). However, hemag­
glutination, oligomerization, C1q binding, and complement 
activation were not affected by this charge modification (Table 5; 
Figures 7C–E). The results indicate that the four analyzed resi­
dues have only limited impact on the IgG3 properties. We cannot 
exclude that other charged residues within the CH2 domain of 
IgG3 may influence or determine properties of this isotype.
DiscUssiOn
We summarized the results of the experiments in Table  6. We 
observed that molecular determinants of the unique features of 
IgG3 are present in the CH2 domain. However, the modifications 
of CH2 differently affected the features suggesting that their 
molecular bases are different.
The prominent role of the CH2 domain in IgG3 biology was 
originally reported by Hovenden et  al. (9). The authors inves­
tigated highly protective IgG3 antibodies against the capsular 
antigen of B. anthracis. They generated an IgG3 mutein with 
CH2 swapped from non­protective IgG2b. The mutein lost pro­
tective activity of the parental molecule and had reduced affinity 
to the antigen. In contrast to the work of Hovenden et  al., we 
generated, for the first time, an antibody mutein that gained the 
unique properties of IgG3. We swapped IgG3­derived CH2 into 
IgG1, and the obtained molecule (IgG1_CH2­3) had properties 
typical for IgG3—it agglutinated erythrocytes, oligomerized, 
had increased functional affinity to a polyvalent antigen, and 
activated the complement cascade. Thus, we proved that these 
unique features of mouse IgG3 could be transferred into a new 
antibody framework.
The mechanism of IgG3­dependent hemagglutination is still 
not completely understood. We previously reported that F(ab’)2 of 
IgG3 is sufficient to agglutinate erythrocytes (11). Here, we show 
that the presence of the CH2 domain in the IgG3 molecule pro­
foundly diminishes the antibody concentration required for the 
F(ab’)2­mediated process. Moreover, the introduction of IgG3­
derived CH2 into IgG1 framework resulted in the IgG1_CH2­3 
mutein that agglutinates erythrocytes. The results indicate that 
efficient hemagglutination is triggered only by the antibodies 
equipped with the IgG3­derived CH2 domain.
The CH2 domain of IgG3 is positively charged at neutral pH. In 
contrast, the CH2 domains of other IgG subclasses are negatively 
FigUre 7 | Properties of the muteins with modified charge of the CH2 domain. (a) Charge location on the CH2 domain of IgG1 and IgG3. Basic residues (Arg, His, 
and Lys) are faint red, acidic residues (Asp, Glu) are blue, and a site of CH2 N-glycosylation (Asn297) is green. His274, Lys282, Arg315, and Lys326 of IgG3 CH2 
are dark red. These four residues were swapped between IgG1 and IgG3 to generate IgG1_CH2charge and IgG3_CH2charge muteins. The images present views 
obtained by 90° rotation of the domain models. (B) Antigen binding by the muteins. The charts present representative results of two independent experiments 
performed in duplicates or triplicates. Error bars equal to SD. (c) Oligomerization of the muteins. Results from two independent experiments with 100 µg/ml of the 
antibodies (M18 variants) are shown. A percentage of the total IgG3-biotin detected in precipitates and supernatants are presented in Figure S4 in Supplementary 
Material. Results for IgG1 and IgG3 are the same as in Figure 4 because the data were collected in the same experiments. (D) C1q binding by the muteins (O10 
variants, 3 µg/ml). Data used for calculation of the normalized binding are shown in Figure S7 in Supplementary Material. The chart presents representative results  
of two independent experiments. Error bars correspond to uncertainty calculated as presented in Section “Materials and Methods.” (e) Complement cascade 
activation by the muteins (3 µg/ml). Erythrocytes coated with the antibodies were incubated with complement serum. Complete lysis (100%) corresponds to 
water-induced lysis. Representative results of two independent experiments are shown.
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TaBle 6 | Summary of experimental results.
igg3 feature/function influence by the ch2 domain
Presence net chargea glycosylation
Hemagglutination Strong 
enhancement
No effect Enhancement
Functional affinity to  
polyvalent antigens
Strong 
enhancement
Weak to  
moderate effect
No effect
Oligomerization in solution Dependence No effect No effect
Activation of complement 
cascade
Dependence No effect Dependenceb
aAssociated with the presence of His274, Lys282, Arg315, Lys326.
bData not shown.
TaBle 5 | Hemagglutination induced by the muteins with modified charge of the CH2 domain.
M18 variants O10 variants
conc. (μg/ml) igg1 igg3 igg1_ch2charge igg3_ch2charge conc. (μg/ml) igg1 igg3 igg1_ch2charge igg3_ch2charge
5.00 ±a ++++ – +++ 2.00 – ++++ ± ++++
2.50 – ++++ – +++ 1.00 – +++ – +++
1.25 – +++ – ++ 0.50 – ++ – ++
0.63 – ++ – ++ 0.25 – ± – ±
0.31 – + – ± 0.13 – – – –
0.16 – ± – – 0.06 – – – –
0.00 – – – – 0.00 – – – –
aRepresentative results of two independent experiments.
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charged under the same condition. Considering that erythrocyte 
surface has a strong negative charge and high zeta potential, it 
was likely that a positive charge of the IgG3­derived CH2 domain 
reduces the zeta potential and as a consequence enhances hema­
gglutination. Unexpectedly, net charge modification of the CH2 
domains in IgG1 and IgG3 did not change hemagglutination 
potential of these isotypes, and we had to reject the hypothesis 
linking the CH2 net charge with the efficiency of hemagglutination.
Alternatively, antibody oligomerization may explain hemag­
glutination enhancement by the CH2 domain of IgG3. We showed 
that this domain solely determined antibody oligomerization in 
solution and thus most probably also on a multi­epitope surface. 
It is possible that oligomerization between antibodies bound to 
separate erythrocytes occurs parallel to a sensitization phase of 
hemagglutination. Thus, antibody oligomerization may lead to 
the formation of zipper­like structures that stabilize cell aggre­
gates and increase a hemagglutination score. Moreover, the CH2 
domain of IgG3 increased functional affinity of an antibody to 
erythrocyte surface. Thus, hemagglutination enhancement may 
at least partially depend on the increased affinity.
However, the observed enhancement of hemagglutination 
by the CH2 domain of IgG3 was affected by enzymatic deglyco­
sylation. In contrast, oligomerization in solution and increased 
functional affinity to polyvalent antigen were independent 
of CH2 glycosylation. This difference indicates that antibody 
oligomerization does not fully account for the CH2 domain­
mediated enhancement of hemagglutination.
Mouse IgG3 has a putative site of N­glycosylation in its CH3 
domain on Asn471. Panka reported that the mutation of this 
Asn residue into Ser diminished the self­association of IgG3 
(17). This finding was later contradicted by Kuroki et al., who 
provided evidence that this putative N­glycosylation site in the 
CH3 domain is not occupied and the mutation Asn471Thr does 
not influence IgG3 self­association or cryoglobulin activity (18). 
Our observations are in line with the findings of Kuroki et al. 
We did not observe any differences between oligomerization of 
IgG3 and its enzymatically deglycosylated variant. It is impor­
tant to note that we and Kuroki et  al. used PEG­precipitation 
for oligomerization analyses. Panka used different methods, 
ELISA and native electrophoresis, which may account for the 
discrepancies.
Greenspan et  al. showed that Fc­dependent oligomerization 
increases functional affinity of IgG3 to polyvalent antigens (5). 
Our results confirm that finding, but we showed that the rela­
tion between oligomerization and increased functional affinity is 
more complex than previously thought. First, functional affinity 
of IgG3 was influenced not only by Fc region (CH2 and CH3 
domains) but also by the CH1 domain. Second, functional affinity 
to the polyvalent antigen (B antigen) was modulated by the CH2 
charge. In contrast, oligomerization in solution required only the 
presence of the CH2 domain of IgG3 and was insensitive to 
the introduced charge modifications. The results showed that 
the mechanism behind high functional affinity may depend on 
more factors than oligomerization in solution does.
The observed influence of the CH1 domain on functional 
affinity is difficult to explain. The CH1 domain of IgG3 has a more 
positive net charge than the CH1 domain of IgG1 (9). It is likely 
that the net charge of the CH1 domain influences the binding of 
the domain muteins to erythrocytes, which have a strong negative 
charge. However, the IgG3­derived CH1 domain also enhanced 
the binding of IgG1_CH1­3 to a surface with the immobilized 
trisaccharide B­BSA conjugate. Thus, the results support previous 
observations (23) that the CH1 domain may influence a variable 
domain and a paratope of an antibody.
According to the general view, the Fab and Fc fragments are 
independent parts of an antibody (24). However, our results dem­
onstrate that the Fc, particularly its CH2 domain, may influence 
Fab­mediated antigen binding. There are two possible mechanisms 
of this phenomenon—intramolecular signaling (25) [called by 
some authors as an intramolecular allostery (16)] or intermolecu­
lar cooperativity.
There are several examples of intramolecular signaling 
observed by different authors investigating how the isotype 
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switching changes an antibody affinity to its antigen [reviewed in 
Ref. (16, 26)]. The effects of the CH1 domains or Fc fragments on 
variable regions are well documented, but considered a rather 
unique phenomenon (16). It is more likely that the increased 
affinity of IgG3 to its antigen results from cooperativity of its CH2 
domains. Within this domain, a specific site of self­association may 
be present, which governs oligomerization of an antibody and pre­
determines the increased affinity to multivalent antigens. However, 
we cannot exclude other scenarios—the involvement of both the 
CH2 and CH3 domains in IgG3 intermolecular interactions or 
even sole CH3­CH3 interactions, assuming that the CH2 domains 
influence the whole molecule structure and promote reciprocal 
interactions of the CH3 domains of neighboring molecules.
Other factors, e.g., influence of the CH1 domain on a paratope, 
properties of an antigen (charge), spatial distribution of epitopes, 
intermolecular forces between epitope and paratope, or a variable 
domain framework may further modulate functional affinity of 
IgG3 upon multivalent antigen binding.
Diebolder at al. described recently an interesting example of 
Fc­dependent antibody oligomerization. Analyses of antibody 
binding to DNP­labeled liposomes (a multivalent antigen) revealed 
that human IgG may form hexamers through non­covalent 
interactions between their constant regions (27). Several muta­
tions that enhance these interactions and subsequent complement 
activation were reported (27). The Fc­interactions promoting 
antibody hexamerization did not change affinity to the cognate 
antigen. Thus, this phenomenon seems to be different from IgG3 
oligomerization, and it is still an open question whether mouse 
antibodies are able to form such hexamers.
Currently, no structure is available for a full­length mouse 
IgG3 or its Fc fragment. We performed some analyses using a 
molecular model of IgG3 obtained by comparative modeling, but 
its resolution is not sufficient for in­depth studies. IgG3 crystal­
lization might provide a direct insight into the mechanism of its 
oligomerization, as was in the case of human IgG1 hexameriza­
tion described in the cited work (27).
Complement cascade activation, as an effector function of 
antibodies, constitutes a first­line of defense against microbial 
infections. As the cascade progresses, components of the comple­
ment are deposited on a pathogen surface and act as opsonins 
for phagocytic cells. Moreover, the complement lyses invading 
pathogens by forming membrane attacking complex. We con­
firmed that C1q­binding motifs, known from human IgG1, are 
functional in the mouse IgG3 framework. On the other hand, we 
did not observe complement activation by mouse IgG1 equipped 
with the motifs. The results indicate that the presence of the known 
C1q­binding motifs is not sufficient for complement activation 
by an antibody. The motifs must be surrounded by a permissive 
framework, provided e.g., by human IgG1 or mouse IgG3.
Our work suggests that a novel type of monoclonal antibod­
ies may be generated by replacing the CH2 domain of a human 
antibody with the homologs fragment of mouse IgG3. Human 
IgG1 subclass is the most feasible target framework for gen­
eration of such IgG3­inspired hybrid mouse/human molecule 
(28). Our observation indicates that the generated hybrid anti­
body should preserve the ability to activate complement and 
may have increased affinity to polyvalent antigens. Since the 
mouse IgG3 subclass is highly protective against several life­ 
threatening microbial infections, the hybrid molecule may be 
very useful in preventing or fighting lethal pathogens. However, 
the hybrid antibody with the mouse CH2 may be immuno­
genic. To decrease the risk of an unwanted immune response, 
the mouse component should be reduced to a minimum. Thus, 
the properties of the CH2 domain derived from mouse IgG3 
should be further investigated and efforts should be made espe­
cially to identify fragments of this domain that determines its 
properties.
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